Detalhe da pesquisa
1.
Research priorities for mitochondrial disorders: Current landscape and patient and professional views.
J Inherit Metab Dis;
45(4): 796-803, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35543492
2.
Reporting the whole story: Analysis of the 'out-of-scope' questions from the James Lind Alliance Teenage and Young Adult Cancer Priority Setting Partnership Survey.
Health Expect;
24(5): 1593-1606, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34247435
3.
Evaluation of the impact of patient input in health technology assessments at NICE.
Int J Technol Assess Health Care;
37: e33, 2021 Jan 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33509314
4.
Understanding and using patient experiences as evidence in healthcare priority setting.
Cost Eff Resour Alloc;
17: 20, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31572067
5.
An operationalization framework for lifecycle HTA.
Int J Technol Assess Health Care;
: 1-29, 2024 May 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38751240
6.
Lifecycle HTA: Promising applications and a framework for implementation.
Int J Technol Assess Health Care;
: 1-25, 2024 May 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38727087
7.
The top 10 research priorities in bleeding disorders: a James Lind Alliance Priority Setting Partnership.
Br J Haematol;
186(4): e98-e100, 2019 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31016727
8.
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions.
J Comp Eff Res;
13(2): e230145, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38226913
9.
Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments.
Patient;
16(1): 7-17, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36217098
10.
Together4RD position statement on collaboration between European reference networks and industry.
Orphanet J Rare Dis;
18(1): 272, 2023 09 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37670358
11.
Consideration of quality of life in the health technology assessments of rare disease treatments.
Eur J Health Econ;
23(4): 645-669, 2022 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34714428
12.
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Pharmacoeconomics;
39(9): 1021-1044, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34231135
13.
Exploring the Burden of X-Linked Hypophosphataemia: An Opportunistic Qualitative Study of Patient Statements Generated During a Technology Appraisal.
Adv Ther;
37(2): 770-784, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31865548
14.
Rare musculoskeletal diseases in adults: a research priority setting partnership with the James Lind Alliance.
Orphanet J Rare Dis;
15(1): 117, 2020 05 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32430048
15.
HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Health Policy;
123(2): 140-151, 2019 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28400128
16.
Research priorities for young people with cancer: a UK priority setting partnership with the James Lind Alliance.
BMJ Open;
9(8): e028119, 2019 08 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31383701
17.
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
Orphanet J Rare Dis;
12(1): 50, 2017 03 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28283046
18.
The Role of Patient Experience in the Value Assessment of Complex Technologies - Do HTA Bodies Need to Reconsider How Value is Assessed?
Health Policy;
125(5): 593-601, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33814201
19.
Research priorities for exacerbations of COPD.
Lancet Respir Med;
9(8): 824-826, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34000234